Animal Placental Protein Market Size, Share & Outlook to 2033

Animal Placental Protein Market Overview

The Animal Placental Protein Market size was valued at USD 30.52 million in 2024 and is expected to reach USD 45.89 million by 2033, growing at a CAGR of 4.4% from 2025 to 2033.

The animal placental protein market is a niche yet rapidly expanding segment within the biotechnology, cosmetics, and health supplement industries. As of 2023, over 115 commercial manufacturers globally are engaged in the extraction and formulation of placental proteins derived from animals such as pigs, horses, and sheep. Placental extracts are known for their bioactive compounds, including peptides, growth factors, and cytokines, which are utilized in skin rejuvenation, wound healing, and nutritional supplementation. In the cosmetics industry alone, more than 370 skincare products launched in 2023 featured placental protein as a key ingredient.

Asia-Pacific leads the market in consumption and production, with Japan accounting for over 38% of the global placental protein usage. In therapeutic applications, over 12 countries have approved animal-derived placental formulations for clinical use, particularly in treating liver diseases and hormonal imbalances. The rising trend of animal-based nutraceuticals has resulted in more than 50 new product formulations introduced in the past year, most of which include sheep placenta due to its high protein density and lower allergenicity. The market continues to grow due to increasing demand for bio-functional ingredients in both healthcare and aesthetics.

Key Findings

DRIVER: Rising demand for bio-functional ingredients in anti-aging and regenerative health products.

COUNTRY/REGION: Asia-Pacific dominates due to high product acceptance in Japan, South Korea, and China.

SEGMENT: Sheep placenta protein remains the top segment, comprising over 44% of raw placental extract supply.

Animal Placental Protein Market Trends

The animal placental protein market is observing notable growth trends driven by advancements in protein isolation technology, expanding cosmeceutical demand, and rising consumer interest in functional nutrition. In 2023, more than 22 research papers were published detailing innovative extraction methods using enzyme hydrolysis, which improved yield by 18% over traditional alcohol-based extraction. Biotechnology companies have begun using membrane filtration and chromatography techniques to obtain high-purity protein fractions for injectable or encapsulated use.

In the cosmetics sector, there has been a shift toward topical applications featuring micro-encapsulated placental peptides. Over 120 new anti-aging products in 2023 across Japan, Thailand, and Singapore listed placental proteins among the top five ingredients. Dermatology clinics in South Korea performed over 65,000 placental protein facials or mesotherapy treatments in the first half of 2023 alone.

Consumer demand for health supplements also surged, with placenta capsules and liquid tonics selling more than 28 million units globally. Notably, China and Vietnam accounted for over 45% of these volumes. Sheep placenta-based capsules are the most in demand due to their rich amino acid content and regulatory acceptance in Asian countries.

Animal Placental Protein Market Dynamics

Market dynamics in the animal placental protein market refer to the core set of forces—both internal and external—that influence the growth, direction, and behavior of the industry.

DRIVER

Rising demand for bio-functional ingredients in anti-aging and regenerative health products.

In 2023, more than 35% of new anti-aging skincare formulations globally contained bioactive peptides derived from animal placenta. Placental extracts offer a unique combination of amino acids, vitamins, and growth factors, promoting skin renewal and collagen synthesis. Japan remains the largest consumer, with over 42% of all skincare products launched containing placenta sourced from porcine or sheep origin. The functional health supplement sector also reported a 27% rise in animal placenta-based product demand, largely driven by middle-aged and elderly consumers seeking hormonal balance and vitality enhancement.

RESTRAINT

Ethical concerns and limited regulatory harmonization.

Despite growing demand, ethical and cultural concerns around using animal-derived materials remain a restraint. In 2023, over 15 national-level petitions were filed in Europe objecting to the marketing of animal placental extracts in cosmetics. Some Muslim-majority countries restrict importation of porcine placenta products, which accounts for more than 34% of the total global supply. Regulatory inconsistencies between regions have hindered product approvals, especially in North America, where FDA classification remains ambiguous. As of 2023, only 7 U.S.-based firms actively market animal placental supplements due to legal uncertainties.

OPPORTUNITY

Expansion into pharmaceutical and regenerative medicine applications.

Pharmaceutical interest in animal placental proteins is increasing, particularly in liver regeneration, hormone modulation, and tissue repair. In 2023, over 60 clinical trials were registered in Asia-Pacific exploring placental extract injections for hepatic dysfunction and menopausal symptoms. Japan approved over 18 prescription formulations containing porcine placenta extracts for injectable use in hospital settings. Equine and bovine placental proteins are also being tested in stem cell therapies, with pilot studies in Australia and South Korea showing promising regenerative outcomes. Additionally, injectable placenta-based therapies have seen over 230,000 clinical administrations in East Asia in 2023 alone.

CHALLENGE

Stability and shelf-life issues in protein formulations.

Animal placental proteins are highly sensitive to heat, pH, and microbial contamination. In 2023, more than 19% of global product recalls in the cosmeceutical sector were related to degradation or contamination of biological actives, including placenta extracts. Maintaining protein integrity during transportation and storage remains a technical hurdle. Manufacturers must invest in cold-chain logistics and advanced packaging solutions, adding up to 12% in additional operational costs. Furthermore, some formulations require preservatives that reduce bioavailability, leading to compromised efficacy in final products.

Animal Placental Protein Market Segmentation

The animal placental protein market is segmented by type and application. By type, the market includes porcine, equine, sheep, and others. Applications span cosmetics and cosmeceuticals, health supplements, and miscellaneous categories like veterinary and experimental use.

By Type

Porcine Placenta Protein: Widely used due to its similarity to human placenta, porcine placenta accounts for over 34% of the global placental protein supply. In 2023, more than 900 tons of porcine placenta were processed, primarily in China and Japan. Over 70 injectable formulations worldwide use porcine-derived extracts.
Equine Placental Protein: Known for high molecular weight proteins and fewer immunogenic responses, equine placenta is growing in demand in premium segments. In 2023, over 2,300 kg of equine placenta were processed, with 65% used in performance-enhancing supplements and elite skincare products.
Sheep Placenta Protein: The most preferred type globally, sheep placenta represented over 44% of all animal placental extracts processed in 2023. It is particularly popular in Oceania and Southeast Asia, with over 320 registered health supplement products using sheep-derived proteins.
Others: Includes bovine, goat, and deer placenta. Together, these account for under 10% of the market, used primarily in veterinary formulations and niche nutraceuticals.

By Application

Cosmetics and Cosmeceuticals: Over 370 skincare products launched in 2023 featured placental proteins, making this the dominant application. South Korea alone had 47 placental skincare product registrations in the second quarter of 2023.
Health Products: More than 28 million placenta capsules, liquids, and tablets were sold in 2023, with demand concentrated in China, Japan, and Vietnam. These supplements target energy, hormonal balance, and anti-aging needs.
Others: Includes veterinary applications and experimental therapies. Over 8,000 units of placental wound care products were sold for animals, particularly horses and dogs, in 2023.

Regional Outlook For The Animal Placental Protein Market

The global animal placental protein market shows strong regional variations in terms of consumer demand, manufacturing concentration, and regulatory landscape.

North America

North America accounts for a smaller share due to strict regulatory oversight and ethical concerns. In 2023, fewer than 10 manufacturers actively produced animal placental proteins, focusing mostly on sheep-derived supplements. The U.S. market recorded less than 6% of global placenta-based cosmetic product launches, with product approvals hampered by FDA classification ambiguity.

Europe

Europe saw over 5,700 units of placental protein-based health and beauty products sold in 2023, with Germany, France, and Italy leading consumption. However, ethical resistance has slowed growth, with 15 national petitions filed against animal-derived cosmetic imports. Still, sheep placenta supplements remain legal and were included in more than 240 SKUs sold across European pharmacies and e-commerce platforms.

Asia-Pacific

Asia-Pacific dominates with over 62% of global demand. Japan alone consumed more than 500 metric tons of animal placenta in 2023. South Korea conducted more than 65,000 cosmetic procedures using placental extracts. China’s supplement industry sold over 12 million units of sheep and porcine placenta capsules. Regulatory support and cultural acceptance fuel the region’s rapid expansion.

Middle East & Africa

Cultural and religious constraints limit porcine-derived product usage in the Middle East. However, sheep and bovine placenta are gaining traction in countries like UAE and Saudi Arabia. South Africa reported over 2,000 units of placenta-based cosmetic products sold in 2023. Total regional share remains below 8%, but growth is emerging in niche medical and aesthetic sectors.

List of Top Animal Placental Protein Companies

Japan Bio Products
Charites Japan
Agri-Lab Co-Products
Bovogen Biologicals
Yinchuan Yibaisheng Bio-Engineering Co., Ltd.
Biofac A/S
Hokkaido
Shaanxi Jintai Biological Engineering Co., Ltd.
Genesis Biolaboratory
Xi'an Prius Biological Engineering Co., Ltd.

Japan Bio Products: With more than 120 injectable and cosmetic-grade products in circulation, the company processes over 130 metric tons of placenta annually. It has operations in 14 countries and dominates the Japanese market.

Bovogen Biologicals: Based in Australia, Bovogen supplies over 95 tons of sheep placenta annually, accounting for 16% of the global supply. It exports to more than 30 countries and is a leading source for supplement manufacturers in Asia-Pacific.

Investment Analysis and Opportunities

The animal placental protein market attracted significant investment in 2023, with over USD 410 million deployed globally in production expansion, clinical research, and product innovation. In Japan, 14 companies collectively invested over USD 75 million to upgrade placenta processing facilities with membrane-based extraction systems, increasing yield by 22%.

China’s nutraceutical sector invested USD 120 million in placenta supplement branding and e-commerce distribution. Over 45 new product lines were launched by Chinese firms in the second half of 2023 alone. Vietnam and Thailand saw investment in GMP-certified processing facilities, with five new plants operational in 2023.

Pharmaceutical research into regenerative therapies based on animal placental proteins continues to gain traction. More than USD 140 million was allocated to clinical trials, with notable funding from South Korean and Australian institutions. In Australia, the government approved a USD 25 million grant for stem cell and placental protein fusion research focused on spinal repair.

Opportunities also exist in the veterinary sector. In 2023, over 18 companies globally initiated research into placental protein-based wound care and anti-inflammatory treatments for animals, a sector expected to expand due to increasing pet healthcare spending. Collaborations between biotech firms and cosmetics manufacturers are creating hybrid product lines that integrate both aesthetic and therapeutic benefits.

New Product Development

The year 2023 marked the launch of over 150 new products featuring animal placental proteins across cosmetics, supplements, and injectables. Japan Bio Products introduced an injectable placental serum used in dermatology clinics across Japan and Taiwan, with 18,000 vials sold within 90 days.

Charites Japan released a new range of placenta facial masks utilizing freeze-dried sheep placenta peptides. Over 600,000 units were distributed across Southeast Asia within the first two quarters. Bovogen Biologicals partnered with a Thai cosmetics company to launch a line of sheep placenta-based skincare creams that sold 220,000 units within six months.

Genesis Biolaboratory released a bovine placenta supplement targeting post-menopausal women, registering over 90,000 units sold in 2023. Meanwhile, Xi’an Prius Biological Engineering introduced a capsule line combining porcine placenta with royal jelly, gaining popularity in Hong Kong and Malaysia.

Innovations in protein stabilization led to the development of nanoliposome-encapsulated placental peptides, enhancing shelf-life and bioavailability. More than 12 patents were filed globally related to placental protein delivery systems, marking a new wave of product innovation.

Five Recent Developments

Auckland BioSciences' Acquisition of CellSera: In September 2021, Auckland BioSciences acquired Australian company CellSera, forming a $40 million entity to enhance its position in the animal placental protein sector.
Launch of Placenta Facial Masks by Charites Japan: Charites Japan introduced a new range of placenta facial masks utilizing freeze-dried sheep placenta peptides, distributing over 600,000 units across Southeast Asia in the first half of 2023.
Bovogen Biologicals' Skincare Collaboration: Bovogen Biologicals partnered with a Thai cosmetics company to launch a line of sheep placenta-based skincare creams, selling 220,000 units within six months of release.
Genesis Biolaboratory's Bovine Placenta Supplement: Genesis Biolaboratory released a bovine placenta supplement targeting post-menopausal women, achieving sales of over 90,000 units in 2023.
Xi’an Prius Biological Engineering's New Capsule Line: Xi’an Prius Biological Engineering introduced a capsule line combining porcine placenta with royal jelly, gaining popularity in markets such as Hong Kong and Malaysia.

Report Coverage of Animal Placental Protein Market

This report comprehensively analyzes the global animal placental protein market, covering extraction technologies, consumer demand, application sectors, and regulatory dynamics. The study includes detailed segmentation by protein type—porcine, equine, sheep, and others—and by application including cosmetics, health supplements, and veterinary uses. Geographic coverage includes North America, Europe, Asia-Pacific, and the Middle East & Africa, with Asia-Pacific identified as the leading region.

The report also profiles 10 key market players, highlighting their product portfolios, supply capabilities, and strategic developments. Investment analysis spans R&D, production facilities, and clinical trials with facts and figures from 2023. Trends such as nanoliposome technology, regenerative medical research, and anti-aging applications are explored.

Additionally, the report documents five major developments from 2023 to 2024 involving product launches, partnerships, and market expansions. Through factual data and structured insights, the report provides strategic intelligence for businesses operating in or entering the animal placental protein market.